Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EBITDA (2016 - 2025)

KalVista Pharmaceuticals' EBITDA history spans 11 years, with the latest figure at -$55.2 million for Q2 2025.

  • On a quarterly basis, EBITDA fell 23.16% to -$55.2 million in Q2 2025 year-over-year; TTM through Apr 2025 was -$182.0 million, a 43.22% decrease, with the full-year FY2025 number at -$185.2 million, down 45.72% from a year prior.
  • EBITDA hit -$55.2 million in Q2 2025 for KalVista Pharmaceuticals, down from -$42.1 million in the prior quarter.
  • Over the last five years, EBITDA for KALV hit a ceiling of -$9.4 million in Q1 2021 and a floor of -$55.2 million in Q2 2025.
  • Historically, EBITDA has averaged -$34.2 million across 4 years, with a median of -$34.3 million in 2024.
  • Biggest five-year swings in EBITDA: decreased 1.63% in 2021 and later crashed 58.36% in 2024.
  • Tracing KALV's EBITDA over 4 years: stood at -$9.4 million in 2021, then plummeted by 201.57% to -$28.2 million in 2023, then tumbled by 49.16% to -$42.1 million in 2024, then plummeted by 31.19% to -$55.2 million in 2025.
  • Business Quant data shows EBITDA for KALV at -$55.2 million in Q2 2025, -$42.1 million in Q4 2024, and -$39.8 million in Q3 2024.